Compimet combines two antihyperglycemic agents with different mechanism of action to improve glycemic control in patients with type 2 diabetes; Pioglitazone Hydrochloride, a member of the Thiazolidinedione class and Metformin Hydrochloride, a member of the Biguanide class.
Pioglitazone, for its mechanism of action, depends on the presence of insulin. Pioglitazone decreases insulin resistance in the periphery and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. It also improves abnormality in lipid metabolism by activating PPAR-g receptor.
Metformin Hydrochloride improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin Hydrochloride decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.